Literature DB >> 19568408

Pim-1 kinase expression predicts radiation response in squamocellular carcinoma of head and neck and is under the control of epidermal growth factor receptor.

Katriina Peltola1, Maija Hollmen, Sanna-Mari Maula, Eeva Rainio, Raija Ristamäki, Marjaana Luukkaa, Jouko Sandholm, Maria Sundvall, Klaus Elenius, Päivi J Koskinen, Reidar Grenman, Sirpa Jalkanen.   

Abstract

Pim-1 is an oncogenic serine/threonine kinase with poorly defined function in epithelial cancers. In this study, we determined 1) associations of Pim-1 expression with clinicopathological parameters including responsiveness to irradiation in squamocellular cancers of head and neck and 2) how Pim-1 expression is controlled subsequent to irradiation. Moderate to high expression of Pim-1 correlated to poor response to radiation therapy (P = .003). It is also associated to the expression of epidermal growth factor receptor (EGFR, P < .0001), which has been shown to be activated by irradiation. In radioresistant tumors, irradiation promoted nuclear translocation of Pim-1 (P < .005). When directly testing EGFR dependence of Pim-1 expression, up-regulation and nuclear translocation of Pim-1 could be induced through stimulation of EGFR with its ligands EGF or transforming growth factor alpha. Both ligand- and irradiation-induced changes in Pim-1 expression and localization could be inhibited by the monoclonal anti-EGFR antibody cetuximab and by the tyrosine kinase inhibitor gefitinib also targeting EGFR. These results suggest that irradiation-induced activation of EGFR upregulates Pim-1, and Pim-1 may be used as a novel predictive marker of radiation response in patients with squamocellular cancers of head and neck.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19568408      PMCID: PMC2697349          DOI: 10.1593/neo.81038

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  35 in total

1.  Cutting edge: Transcriptional activity of NFATc1 is enhanced by the Pim-1 kinase.

Authors:  Eeva-Marja Rainio; Jouko Sandholm; Päivi J Koskinen
Journal:  J Immunol       Date:  2002-02-15       Impact factor: 5.422

2.  Pim-1 protein kinase is nuclear in Burkitt's lymphoma: nuclear localization is necessary for its biologic effects.

Authors:  Yurij Ionov; Xuan Le; Brian J Tunquist; John Sweetenham; Traci Sachs; John Ryder; Thomas Johnson; Michael B Lilly; Andrew S Kraft
Journal:  Anticancer Res       Date:  2003 Jan-Feb       Impact factor: 2.480

3.  Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas.

Authors:  T Akimoto; N R Hunter; L Buchmiller; K Mason; K K Ang; L Milas
Journal:  Clin Cancer Res       Date:  1999-10       Impact factor: 12.531

4.  Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase.

Authors:  Zeping Wang; Nandini Bhattacharya; Philip F Mixter; Wenyi Wei; John Sedivy; Nancy S Magnuson
Journal:  Biochim Biophys Acta       Date:  2002-12-16

5.  Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region.

Authors:  Sanna-Mari Maula; Marjaana Luukkaa; Reidar Grénman; David Jackson; Sirpa Jalkanen; Raija Ristamäki
Journal:  Cancer Res       Date:  2003-04-15       Impact factor: 12.701

6.  Pim-1 kinase protects hematopoietic FDC cells from genotoxin-induced death.

Authors:  T J Pircher; S Zhao; J N Geiger; B Joneja; D M Wojchowski
Journal:  Oncogene       Date:  2000-07-27       Impact factor: 9.867

7.  Delineation of prognostic biomarkers in prostate cancer.

Authors:  S M Dhanasekaran; T R Barrette; D Ghosh; R Shah; S Varambally; K Kurachi; K J Pienta; M A Rubin; A M Chinnaiyan
Journal:  Nature       Date:  2001-08-23       Impact factor: 49.962

8.  Overexpression of the oncogenic kinase Pim-1 leads to genomic instability.

Authors:  Meejeon Roh; Bernard Gary; Chisu Song; Nasser Said-Al-Naief; Albert Tousson; Andrew Kraft; Isam-Eldin Eltoum; Sarki A Abdulkadir
Journal:  Cancer Res       Date:  2003-12-01       Impact factor: 12.701

9.  The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells.

Authors:  Marina Zemskova; Eva Sahakian; Svetlana Bashkirova; Michael Lilly
Journal:  J Biol Chem       Date:  2008-04-21       Impact factor: 5.157

10.  Pim-1 associates with protein complexes necessary for mitosis.

Authors:  Nandini Bhattacharya; Zeping Wang; Christine Davitt; Ian F C McKenzie; Pei-Xiang Xing; Nancy S Magnuson
Journal:  Chromosoma       Date:  2002-05-15       Impact factor: 4.316

View more
  41 in total

1.  The interconnectedness of cancer cell signaling.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

Review 2.  For better or for worse: the role of Pim oncogenes in tumorigenesis.

Authors:  Martijn C Nawijn; Andrej Alendar; Anton Berns
Journal:  Nat Rev Cancer       Date:  2010-12-09       Impact factor: 60.716

3.  p53-dependent induction of prostate cancer cell senescence by the PIM1 protein kinase.

Authors:  Marina Zemskova; Michael B Lilly; Ying-Wei Lin; Jin H Song; Andrew S Kraft
Journal:  Mol Cancer Res       Date:  2010-07-20       Impact factor: 5.852

4.  Pim1 kinase is upregulated in glioblastoma multiforme and mediates tumor cell survival.

Authors:  Susann Herzog; Matthias Alexander Fink; Kerstin Weitmann; Claudius Friedel; Stefan Hadlich; Sönke Langner; Katharina Kindermann; Tobias Holm; Andreas Böhm; Eskil Eskilsson; Hrvoje Miletic; Markus Hildner; Michael Fritsch; Silke Vogelgesang; Christoph Havemann; Christoph Alexander Ritter; Henriette Elisabeth Meyer zu Schwabedissen; Bernhard Rauch; Wolfgang Hoffmann; Heyo Klaus Kroemer; Henry Schroeder; Sandra Bien-Möller
Journal:  Neuro Oncol       Date:  2014-08-25       Impact factor: 12.300

5.  PI3K-like kinases restrain Pim gene expression in endothelial cells.

Authors:  Xinwen Min; Jie Tang; Yinfang Wang; Minghua Yu; Libing Zhao; Handong Yang; Peng Zhang; Yexin Ma
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-01-27

Review 6.  Why target PIM1 for cancer diagnosis and treatment?

Authors:  Nancy S Magnuson; Zeping Wang; Gang Ding; Raymond Reeves
Journal:  Future Oncol       Date:  2010-09       Impact factor: 3.404

Review 7.  PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer.

Authors:  Sabina Luszczak; Christopher Kumar; Vignesh Krishna Sathyadevan; Benjamin S Simpson; Kathy A Gately; Hayley C Whitaker; Susan Heavey
Journal:  Signal Transduct Target Ther       Date:  2020-01-31

8.  The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells.

Authors:  F F Blanco; M Jimbo; J Wulfkuhle; I Gallagher; J Deng; L Enyenihi; N Meisner-Kober; E Londin; I Rigoutsos; J A Sawicki; M V Risbud; A K Witkiewicz; P A McCue; W Jiang; H Rui; C J Yeo; E Petricoin; J M Winter; J R Brody
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

9.  The War on Cancer rages on.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

10.  Pim-selective inhibitor DHPCC-9 reveals Pim kinases as potent stimulators of cancer cell migration and invasion.

Authors:  Niina M Santio; Riitta L Vahakoski; Eeva-Marja Rainio; Jouko A Sandholm; Sanna S Virtanen; Michelle Prudhomme; Fabrice Anizon; Pascale Moreau; Päivi J Koskinen
Journal:  Mol Cancer       Date:  2010-10-19       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.